- Previous Close
0.0650 - Open
0.0620 - Bid 0.0600 x --
- Ask 0.0660 x --
- Day's Range
0.0600 - 0.0620 - 52 Week Range
0.0550 - 0.1800 - Volume
378,665 - Avg. Volume
491,002 - Market Cap (intraday)
23.277M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
www.ampliatx.comRecent News: ATX.AX
View MorePerformance Overview: ATX.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATX.AX
View MoreValuation Measures
Market Cap
23.28M
Enterprise Value
18.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-181.41%
Return on Assets (ttm)
-24.61%
Return on Equity (ttm)
-44.96%
Revenue (ttm)
3.41M
Net Income Avi to Common (ttm)
-6.19M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
4.56M
Total Debt/Equity (mrq)
0.43%
Levered Free Cash Flow (ttm)
-799.69k